NELARABINE
Clinical safety rating
cautionComprehensive clinical and safety monograph for NELARABINE (NELARABINE).
Comprehensive clinical and safety monograph for NELARABINE (NELARABINE).
T-cell acute lymphoblastic leukemia (T-ALL)T-cell lymphoblastic lymphoma (T-LBL)Relapsed or refractory T-ALL/T-LBL
Nelarabine is a prodrug of ara-G, a deoxyguanosine analog. It is converted to ara-GTP, which accumulates in T-cells and inhibits DNA synthesis, leading to cell death.
| Metabolism | Nelarabine is demethylated by adenosine deaminase (ADA) to ara-G, which is then phosphorylated to ara-GTP intracellularly. It is partially metabolized by aldehyde oxidase. |
| Excretion | Renal: 50-60% as unchanged ara-G; fecal: <5% as metabolites; biliary: negligible. |
| Half-life | Terminal t1/2: 30 hours (range 21-48 h) in adults; prolonged in renal impairment. Ara-G (active metabolite) t1/2: 3 hours. |
| Protein binding | <25% bound to plasma proteins (albumin). |
| Volume of Distribution | Vd: 197 L/m² (approx 5.6 L/kg based on 1.73 m²/70 kg), indicating extensive tissue distribution. |
| Bioavailability | IV only; oral bioavailability not established (<5% due to extensive first-pass metabolism). |
| Onset of Action | IV: Clinical response (e.g., reduction in blasts) observed within 1-2 weeks after first dose; peak plasma concentration occurs at end of infusion. |
| Duration of Action | Duration of response variable; typical cycle length 21-28 days with dosing on days 1, 3, 5. Cytotoxic effects persist for several days post-infusion. |
| Molecular Weight | 297.3 |
1500 mg/m2 intravenously over 2 hours on days 1, 3, and 5, repeated every 28 days.
| Dosage form | INJECTABLE |
| Renal impairment | CrCl 30-60 mL/min: reduce dose to 975 mg/m2. CrCl <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh Class B or C: reduce dose to 975 mg/m2. No data for severe impairment. |
| Pediatric use | 650 mg/m2 intravenously over 1 hour daily for 5 consecutive days, repeated every 21 days. |
| Geriatric use | No specific dose adjustment recommended; monitor renal function and hematologic toxicity closely. |
| 1st trimester | Nelarabine is embryotoxic and teratogenic in animal studies. Avoid use in first trimester unless potential benefit outweighs risk. |
| 2nd trimester | Limited human data; animal studies show fetal harm. Use only if clearly needed. |
| 3rd trimester | May cause fetal harm; use only if potential benefit justifies risk. |
Clinical note
Comprehensive clinical and safety monograph for NELARABINE (NELARABINE).
| Placental transfer | Nelarabine and its active metabolite ara-G are likely to cross the placenta based on molecular weight and animal studies, but specific human data are limited. |
| Breastfeeding | It is unknown if nelarabine is excreted in human milk. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for at least 1 week after the last dose. |
| Lactation Rating | Avoid |
| Teratogenic Risk | Nelarabine is embryotoxic and fetotoxic in animal studies. It is classified as FDA Pregnancy Category D. There is evidence of fetal harm in pregnant women, including increased risk of congenital malformations, intrauterine growth restriction, and fetal death. Use during the first trimester carries highest risk of major malformations; second and third trimester exposure may cause myelosuppression and low birth weight. Avoid in pregnancy unless benefit outweighs risk. |
| Fetal Monitoring | Monitor complete blood counts weekly during therapy and for at least 6 weeks after last dose due to risk of myelosuppression. Assess liver function tests (ALT, AST, bilirubin) and renal function (serum creatinine) at baseline and periodically. Perform fetal ultrasound for growth and anatomy if pregnancy occurs during treatment. Monitor for signs of neuropathy (gait, motor, sensory) in both mother and neonate. |
| Fertility Effects | Nelarabine may impair fertility in both males and females based on animal studies showing testicular atrophy and ovarian damage. In preclinical studies, reduced spermatogenesis and fertility were observed. Human data are limited; advise fertility preservation counseling prior to treatment. |
■ FDA Black Box Warning
Severe neurotoxicity, including Guillain-Barré-like syndrome, peripheral neuropathy, and CNS demyelination. Avoid in patients with severe pre-existing neurological conditions.
| Serious Effects |
History of hypersensitivity to nelarabine or any component of the formulation
| Precautions | Monitor for neurological toxicity; may require discontinuation., Hematologic toxicity: neutropenia, thrombocytopenia, anemia., Increased risk of infection., Tumor lysis syndrome prophylaxis required., Hepatotoxicity and renal toxicity. |
| Food/Dietary | No known food interactions. Maintain adequate hydration to prevent tumor lysis syndrome. Avoid grapefruit juice? No evidence for interaction. |
| Clinical Pearls | Administer intravenously over 2 hours. Monitor for neurological toxicity including somnolence, ataxia, and seizures. Premedicate with antiemetics. Use in T-cell acute lymphoblastic leukemia/lymphoma after failure of two prior regimens. Contraindicated in severe renal impairment (CrCl <30 mL/min). |
| Patient Advice | This drug can cause severe drowsiness and coordination problems; do not drive or operate machinery until you know how it affects you. · Report any unusual tiredness, muscle weakness, or tingling in hands/feet to your doctor immediately. · If you experience seizures, loss of consciousness, or confusion, seek emergency medical attention. · You will have regular blood tests to monitor your blood cell counts and kidney function. · This drug can cause serious infections; wash hands frequently and avoid crowds. · Use effective contraception during treatment and for at least 3 months after stopping. · Do not receive live vaccines during therapy without consulting your doctor. |
Loading safety data…